%PDF-1.7
%
1 0 obj
<>
endobj
84 0 obj
<>/Font<>>>/Fields 88 0 R>>
endobj
4 0 obj
<>stream
Acrobat Distiller 5.0 (Windows)
2010-03-24T11:33:57Z
2012-04-25T08:43:08-03:00
2012-04-25T08:43:08-03:00
PScript5.dll Version 5.2.2
application/pdf
Jr
FARMACIA.pdf
uuid:0a5ef697-3bac-4546-a0e6-9f6e539a5d78
uuid:2add9a5d-6457-4093-a998-c962c883c6f4
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
47 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
50 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
60 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
70 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
73 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
76 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/TrimBox[6.96001 31.27499 588.06 810.825]/Type/Page>>
endobj
107 0 obj
<>stream
q
6.96 31.294 581.101 779.552 re
W n
/CS0 CS 0.137 0.122 0.125 SCN
0.992 w 1000 M
/GS0 gs
q 1 0 0 1 51.129 780.801 cm
0 0 m
0.782 0.782 1.725 1.173 2.831 1.173 c
504.082 1.173 l
505.188 1.173 506.131 0.782 506.913 0 c
507.695 -0.782 508.086 -1.725 508.086 -2.831 c
508.086 -718.082 l
508.086 -719.188 507.695 -720.131 506.913 -720.913 c
506.131 -721.695 505.188 -722.086 504.082 -722.086 c
2.831 -722.086 l
1.725 -722.086 0.782 -721.695 0 -720.913 c
-0.782 -720.131 -1.173 -719.188 -1.173 -718.082 c
-1.173 -2.831 l
-1.173 -1.725 -0.782 -0.782 0 0 c
S
Q
Q
/CS0 CS 0.137 0.122 0.125 SCN
0.992 w
/GS0 gs
q 1 0 0 1 304.102 768.321 cm
0 0 m
0 -694.546 l
S
Q
BT
/CS1 cs 1 scn
/T1_0 1 Tf
8 0 0 8 555.4071 44.7198 Tm
(7)Tj
/CS2 cs 1 scn
/T1_1 1 Tf
6 0 0 6 49.4503 49.1698 Tm
(M)Tj
0.0118 Tc 4.2 0 0 4.2 54.4677 49.1698 Tm
[(INIST\311RIO)-603(D)11(A)]TJ
0.1463 Tc 6 0 0 6 84.3732 49.1698 Tm
( S)Tj
0.0076 Tc 4.2 0 0 4.2 90.9496 49.1698 Tm
(A\332DE)Tj
/CS1 cs 1 scn
0 Tc 6 0 0 6 49.4503 41.9697 Tm
(F)Tj
-0.0099 Tc 4.2 0 0 4.2 53.107 41.9697 Tm
(UNDA\307\303O)Tj
0.0772 Tc 6 0 0 6 73.8566 41.9697 Tm
( N)Tj
-0.0095 Tc 4.2 0 0 4.2 80.3196 41.9697 Tm
[(ACIONAL)-522(D)9(E)]TJ
0.0802 Tc 6 0 0 6 106.3984 41.9697 Tm
( S)Tj
-0.0126 Tc 4.2 0 0 4.2 112.5492 41.9697 Tm
(A\332DE)Tj
-0.0063 Tc 0.085 Tw 6 0 0 6 124.0582 41.9697 Tm
( - FUNASA)Tj
ET
/CS3 cs 0 scn
225.51 794.97 161.3 -22.5 re
f
BT
/CS1 cs 1 scn
/T1_2 1 Tf
-0.0059 Tc 0.0522 Tw 9 0 0 9 225.5674 781.9272 Tm
[(N\315VEL)32( SUPERIOR - \301REA)51( - F)82(ARM\301CIA)]TJ
/T1_0 1 Tf
0.0002 Tc 0 Tw -17.991 -2.312 Td
(54.)Tj
/T1_3 1 Tf
-0.0158 Tc -0.0541 Tw 2.268 0 Td
(O processo de armazenamento de medicamentos e correlatos \351)Tj
-0.0083 Tw -0.06 -1.2 Td
(de vital import\342ncia, a fim de que estes n\343o apresentem modi-)Tj
-0.0191 Tc -0.0627 Tw 0 -1.2 TD
(fica\347\365es organol\351pticas, guardando, na \355ntegra, a total ativ\
idade)Tj
-0.0147 Tc -0.0494 Tw T*
(de seus princ\355pios ativos. Para tanto, cuidados devem ser cons-)Tj
-0.0163 Tc 0.0411 Tw T*
(tantemente tomados na manipula\347\343o, acondicionamento, em-)Tj
-0.0072 Tw T*
(balagem e estocagem desses insumos. Sabemos que in\372meros)Tj
-0.0149 Tc 0.113 Tw T*
(fatores de natureza INTR\315NSECA e EXTR\315NSECA provo-)Tj
-0.0154 Tc 0.0643 Tw T*
(cam altera\347\365es nesses produtos. Est\343o indicados somente fa-)Tj
-0.015 Tc 0.0153 Tw T*
(tores INTR\315NSECOS na seguinte alternativa:)Tj
-0.0047 Tc 0.0222 Tw 0 -1.518 TD
[(A)-33(\))-808(pH e calor)]TJ
-0.009 Tc -0.0611 Tw 0 -1.515 TD
[(B)-7(\))-897(umidade e radia\347\343o)]TJ
-0.0054 Tc -0.0132 Tw 0 -1.518 TD
[(C\))-894(recipientes e agentes microbianos)]TJ
-0.0062 Tc -0.0592 Tw 0 -1.515 TD
[(D)-35(\))-809(incompatibilidade f\355sico-qu\355mica e hidr\363lise)]TJ
-0.0056 Tc 0.0857 Tw 0 -1.518 TD
[(E)22(\))-976(oxig\352nio do ar atmosf\351rico e problemas resultantes de)]TJ
-0.0085 Tc -0.0611 Tw 1.887 -1.2 Td
(rea\347\365es de oxirredu\347\343o)Tj
/T1_0 1 Tf
0.0002 Tc 0 Tw -4.094 -2.46 Td
(55.)Tj
/T1_3 1 Tf
-0.0055 Tc -0.0623 Tw 2.268 0 Td
(O bloqueador do canal de c\341lcio que deprime a velocidade do)Tj
-0.005 Tc 0.1155 Tw -0.06 -1.2 Td
[(marca-passo do nodo sinusal e torna lenta a condu\347\343o )52(A)128(V)]TJ
-0.0055 Tc -0.0277 Tw 0 -1.2 TD
(\(atrioventricular\) \351:)Tj
-0.0061 Tc 0 Tw 0 -1.518 TD
[(A)-35(\))-809(nifedipina)]TJ
-0.0432 Tc 0 -1.515 TD
[(B)-42(\))-931(nimodipina)]TJ
0.0312 Tc 0 -1.518 TD
[(C)33(\))-857(verapamil)]TJ
-0.0083 Tc 0 -1.515 TD
[(D)-37(\))-811(nicardipina)]TJ
-0.0027 Tc 0 -1.518 TD
[(E)25(\))-973(pentamidina)]TJ
/T1_0 1 Tf
0.0002 Tc -2.208 -2.46 Td
(56.)Tj
/T1_3 1 Tf
-0.004 Tc 0.125 Tw 2.268 0 Td
(O principal ant\355doto para o tratamento de intoxica\347\343o por)Tj
-0.0066 Tc -0.0222 Tw -0.06 -1.2 Td
(paracetamol \351:)Tj
-0.0001 Tc 0 Tw T*
[(A)-29(\))-803(dipirona)]TJ
-0.0238 Tc 0 -1.515 TD
[(B)-22(\))-912(naloxona)]TJ
-0.0122 Tc 0 -1.518 TD
[(C)-11(\))-900(flumazenil)]TJ
0.0052 Tc 0 -1.515 TD
[(D)-23(\))-798(atovastatina)]TJ
-0.0073 Tc 0 -1.518 TD
[(E)20(\))-977(N-acetilciste\355na)]TJ
/T1_0 1 Tf
0.0002 Tc 25.354 42.072 Td
(57.)Tj
/T1_3 1 Tf
-0.0052 Tc 0.0722 Tw 2.268 0 Td
(A ingest\343o excessiva de acetoaminofen provoca, principal-)Tj
-0.0054 Tc -0.0482 Tw -0.063 -1.2 Td
(mente, a seguinte rea\347\343o:)Tj
0.0129 Tc -0.0611 Tw T*
[(A)-16(\))-793(toxicidade card\355aca)]TJ
-0.0053 Tc -0.0615 Tw 0 -1.515 TD
[(B\))-897(toxicidade hep\341tica)]TJ
-0.0125 Tc -0.0611 Tw 0 -1.518 TD
[(C)-11(\))-904(toxicidade renal)]TJ
0.0029 Tc 0 Tw 0 -1.515 TD
[(D)-26(\))-803(pancreatite)]TJ
0.0062 Tc 0 -1.518 TD
[(E)34(\))-967(estomatite)]TJ
/T1_0 1 Tf
0.0002 Tc -2.205 -2.46 Td
(58.)Tj
/T1_3 1 Tf
-0.0051 Tc 0.0361 Tw 2.268 0 Td
(A alternativa que menciona o principal \363rg\343o relacionado \340)Tj
-0.0061 Tc -0.0204 Tw -0.063 -1.2 Td
(elimina\347\343o de f\341rmacos e seus metab\363litos \351:)Tj
0.0002 Tc 0 Tw T*
[(A)-28(\))-806(p\342ncreas)]TJ
-0.0159 Tc 0 -1.515 TD
[(B)-14(\))-907(ves\355cula)]TJ
-0.0279 Tc 0 -1.518 TD
[(C)-26(\))-919(f\355gado)]TJ
0.1386 Tc 0 -1.515 TD
[(D)-57(\))-501(rim)]TJ
0 Tc 0 -1.518 TD
[(E)28(\))-973(pele)]TJ
/T1_0 1 Tf
0.0002 Tc -2.205 -2.46 Td
(59.)Tj
/T1_3 1 Tf
-0.0056 Tc 0.1181 Tw 2.268 0 Td
(Dentre os sistemas de distribui\347\343o de medicamentos, o de)Tj
-0.0053 Tc -0.0089 Tw -0.063 -1.2 Td
(dose unit\341ria apresenta a seguinte vantagem:)Tj
-0.0059 Tc -0.0583 Tw T*
[(A)-34(\))-812(manuten\347\343o da qualidade)]TJ
-0.0057 Tc 0.0525 Tw 0 -1.515 TD
[(B\))-897(aumento do tempo de dispensa\347\343o)]TJ
0.0045 Tc -0.0209 Tw 0 -1.518 TD
[(C)6(\))-887(aumento do \355ndice de concentra\347\343o)]TJ
-0.0053 Tc -0.0222 Tw 0 -1.515 TD
[(D)-34(\))-812(redu\347\343o relativa de erros de administra\347\343o)]TJ
-0.0057 Tc -0.0111 Tw 0 -1.518 TD
[(E)22(\))-979(redu\347\343o dos estoques nas unidades de enfermagem)]TJ
/T1_0 1 Tf
0.0002 Tc 0 Tw -2.205 -2.46 Td
(60.)Tj
/T1_3 1 Tf
-0.0054 Tc -0.041 Tw 2.268 0 Td
(O f\341rmaco que aumenta a absor\347\343o de digoxina \351:)Tj
-0.0033 Tc 0 Tw -0.063 -1.518 Td
[(A)-32(\))-810(diltiazen)]TJ
-0.0061 Tc 0 -1.515 TD
[(B\))-897(albuterol)]TJ
0.0026 Tc 0 -1.518 TD
[(C\))-889(omeprazol)]TJ
0.0418 Tc T*
[(D)-69(\))-683(neomicina)]TJ
-0.0068 Tc 0 -1.515 TD
[(E)21(\))-980(sulfasalazina)]TJ
1 0 0 rg
/GS1 gs
/TT0 12 Tf
0.5762 Tc 1 0 0 1 373.2224 12 Tm
(\r\n)Tj
ET
q
1 0 0 1 219.125 8.7720337 cm
0 g
0 G
1 w
0 Tc /Fm0 Do
Q
endstream
endobj
109 0 obj
<>/Subtype/Form/Type/XObject>>stream
1 g
1 0 0 1 0 0 cm
220.625 10.272 m
372.6459 10.272 l
372.6459 22.368 l
220.625 22.368 l
220.625 10.272 l
f
endstream
endobj
7 0 obj
<>
endobj
10 0 obj
<>
endobj
13 0 obj
<>
endobj
16 0 obj
<>
endobj
82 0 obj
<>
endobj
81 0 obj
<>
endobj
17 0 obj
<>
endobj
18 0 obj
<>stream
HT[p]HZ*^]]J܄&!S:aB$,Ɗm-ziزeVOK$[,Ʈ1q+Lm:eL:LY9Lۯ